scholarly journals Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

2014 ◽  
Vol 85 (4) ◽  
pp. 962-971 ◽  
Author(s):  
Donald E. Kohan ◽  
Paola Fioretto ◽  
Weihua Tang ◽  
James F. List
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Renal Impairment ◽  
Moderate Renal Impairment ◽  
Term Study ◽  
Long Term Study

scholarly journals Glycemic Control and Hypoglycemia Benefits with Insulin Glargine 300 U/mL (Gla-300) Extend to People with Type 2 Diabetes and Mild-to-Moderate Renal Impairment

2016 ◽  
Vol 40 (5) ◽  
pp. S47
Author(s):  
Peter A. Senior ◽  
Javier Escalada ◽  
Serge Halimi ◽  
Mireille Bonnemaire ◽  
Anna M.G. Cali ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Renal Impairment ◽  
Insulin Glargine ◽  
Moderate Renal Impairment

scholarly journals Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-year Non-randomized Clinical Trial

2018 ◽  
Author(s):  
Shaminie J. Athinarayanan ◽  
Rebecca N. Adams ◽  
Sarah J. Hallberg ◽  
Amy L. McKenzie ◽  
Nasir H. Bhanpuri ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Medication Use ◽  
Controlled Study ◽  
Cardiometabolic Health ◽  
Diabetes Medication ◽  
Care Intervention

ABSTRACTOBJECTIVEStudies on long-term sustainability of low-carbohydrate approaches to treat diabetes are limited. We aim to assess the effects of a continuous care intervention (CCI) on retention, glycemic control, weight, body composition, cardiovascular, liver, kidney, thyroid, inflammatory markers, diabetes medication usage and disease outcomes at 2 years in adults with type 2 diabetes (T2D).RESEARCH DESIGN AND METHODSAn open label, non-randomized, controlled study with 262 and 87 participants with T2D were enrolled in the CCI and usual care (UC) groups, respectively.RESULTSSignificant changes from baseline to 2 years in the CCI group included: HbA1c (−12% from 7.7±0.1%); fasting glucose (−18% from 163.67±3.90 mg/dL); fasting insulin (−42% from 27.73±1.26 pmol L-1); weight (−10% from 114.56±0.60 kg); systolic blood pressure (−4% from 131.7±0.9 mmHg); diastolic blood pressure (−4% from 81.8±0.5 mmHg); triglycerides (−22% from 197.2±9.1 mg/dL); HDL-C (+19% from 41.8±0.9 mg/dL), and liver alanine transaminase (−21% from 29.16±0.97 U/L). Spine bone mineral density in the CCI group was unchanged. Glycemic control medication use (excluding metformin) among CCI participants declined (from 56.9% to 26.8%, P=1.3×10-11) including prescribed insulin (−62%) and sulfonylureas (−100%). The UC group had no significant changes in these parameters (except uric acid and anion gap) or diabetes medication use. There was also significant resolution of diabetes (reversal, 53.5%; remission, 17.6%) in the CCI group but not in UC. All the reported improvements had p-values <0.00012.CONCLUSIONSThe CCI sustained long-term beneficial effects on multiple clinical markers of diabetes and cardiometabolic health at 2 years while utilizing less medication. The intervention was also effective in the resolution of diabetes and visceral obesity, with no adverse effect on bone health.TRIAL REGISTRATIONClinicaltrials.govNCT02519309

Sign in / Sign up

Export Citation Format

Share Document